Kalcijev Folinat Sandoz

Folinic Acid, the active ingredient in Kalcijev Folinat Sandoz, is a folate analog presented as a sterile solution for intramuscular and intravenous use. It is employed to rescue normal cells from the toxic effects of high‑dose methotrexate and to correct folate deficiency in patients undergoing chemotherapy or with inadequate dietary intake.

GNH USA supplies Kalcijev Folinat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to strict quality standards and provides regulatory‑approved documentation for global distribution.

Folinic Acid is used in clinical settings to support folate‑dependent pathways and mitigate toxicity from antifolate agents. - Rescue therapy after high‑dose methotrexate treatment: reduces methotrexate‑induced toxicity and promotes recovery of normal cells. - Prevention and treatment of folate deficiency: restores adequate folate levels in patients with dietary deficiency or increased metabolic demand. - Adjunct in certain chemotherapy regimens: enhances efficacy and reduces side effects of antifolate chemotherapy protocols.

Folinic Acid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Mild fever or chills - Injection‑site pain or erythema - Headache - Transient rash or itching

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Hypotension or cardiovascular collapse - Acute renal impairment - Hepatic dysfunction or jaundice - Pancytopenia or severe bone‑marrow suppression - Severe electrolyte disturbances

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Renal function: assess baseline creatinine and adjust dose if impairment is present. - Hepatic function: monitor liver enzymes, especially in patients with pre‑existing liver disease. - Pregnancy: use only when clearly indicated, after risk‑benefit assessment. - Concomitant methotrexate: ensure appropriate timing to avoid antagonism. - Allergy: avoid in individuals with known hypersensitivity to folinic acid or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Folinic Acid can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - High‑dose methotrexate: may diminish rescue effectiveness if timing is incorrect. - Other antifolate agents (e.g., pemetrexed): concurrent use can reduce therapeutic intent of the antifolate.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance of folinic acid. - Aminoglycoside antibiotics: combined nephrotoxic potential warrants monitoring. - Loop diuretics: can alter renal excretion, requiring dose adjustment. - Proton pump inhibitors: may modestly affect absorption of oral folate analogues, though less relevant for injectable forms.